Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies has expanded its clinical research efforts in bladder cancer treatment by launching three new study sites in the United States. These sites will focus on the investigation of the company’s lead drug, Ruvidar, in a Phase II study targeting BCG-unresponsive non-muscle invasive bladder cancer. With bladder cancer being a significant health concern, these developments mark an important step in addressing the disease.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.